Paul Edwards Posted December 3, 2014 Share Posted December 3, 2014 This post in the New Prostate Cancer Infolink suggests that "the failure of this drug to demonstrate significant efficacy in either one of two Phase III trials for the treatment of metastatic, castration-resistant prostate cancer has surely ended any attempt to develop this drug for the treatment of prostate cancer." Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.